XML 45 R31.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 6,022 | $ 5,422 | $ 11,888 | $ 10,665
United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 4,554 | 4,047 | 8,994 | 7,961
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,468 | 1,375 | 2,894 | 2,704
MedSurg and Neurotechnology: |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 3,771 | 3,215 |  |
MedSurg and Neurotechnology: | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 2,978 | 2,495 | 5,745 | 4,889
MedSurg and Neurotechnology: | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 793 | 720 | 1,537 | 1,423
MedSurg and Neurotechnology: | Instruments |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 768 | 698 | 1,498 | 1,365
MedSurg and Neurotechnology: | Instruments | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 621 | 564 | 1,208 | 1,096
MedSurg and Neurotechnology: | Instruments | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 147 | 134 | 290 | 269
MedSurg and Neurotechnology: | Endoscopy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 899 | 768 | 1,766 | 1,546
MedSurg and Neurotechnology: | Endoscopy | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 742 | 623 | 1,452 | 1,259
MedSurg and Neurotechnology: | Endoscopy | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 157 | 145 | 314 | 287
MedSurg and Neurotechnology: | Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 990 | 908 | 1,935 | 1,772
MedSurg and Neurotechnology: | Medical | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 840 | 763 | 1,642 | 1,478
MedSurg and Neurotechnology: | Medical | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 150 | 145 | 293 | 294
MedSurg and Neurotechnology: | Vascular |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 498 | 327 | 904 | 637
MedSurg and Neurotechnology: | Vascular | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 268 | 127 | 471 | 248
MedSurg and Neurotechnology: | Vascular | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 230 | 200 | 433 | 389
MedSurg and Neurotechnology: | Neuro Cranial |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 616 | 514 | 1,179 | 992
MedSurg and Neurotechnology: | Neuro Cranial | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 507 | 418 | 972 | 808
MedSurg and Neurotechnology: | Neuro Cranial | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 109 | 96 | 207 | 184
Orthopaedics: |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 2,251 | 2,207 | 4,606 | 4,353
Orthopaedics: | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,576 | 1,552 | 3,249 | 3,072
Orthopaedics: | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 675 | 655 | 1,357 | 1,281
Orthopaedics: | Knees |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 640 | 602 | 1,279 | 1,190
Orthopaedics: | Knees | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 460 | 433 | 924 | 862
Orthopaedics: | Knees | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 180 | 169 | 355 | 328
Orthopaedics: | Hips |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 466 | 428 | 909 | 821
Orthopaedics: | Hips | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 283 | 261 | 552 | 512
Orthopaedics: | Hips | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 183 | 167 | 357 | 309
Orthopaedics: | Trauma and Extremities |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 957 | 832 | 1,902 | 1,662
Orthopaedics: | Trauma and Extremities | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 702 | 610 | 1,415 | 1,221
Orthopaedics: | Trauma and Extremities | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 255 | 222 | 487 | 441
Orthopaedics: | Spinal Implants |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 5 | 178 | 171 | 349
Orthopaedics: | Spinal Implants | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 0 | 124 | 118 | 241
Orthopaedics: | Spinal Implants | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 5 | 54 | 53 | 108
Orthopaedics: | Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 183 | 167 | 345 | 331
Orthopaedics: | Other | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 131 | 124 | 240 | 236
Orthopaedics: | Other | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 52 | $ 43 | $ 105 | $ 95

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_MedSurgAndNeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_EndoscopyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeurovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeuroCranialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_OrthopaedicsAndSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_KneesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_HipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_TraumaandExtremitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherOrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |